Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
US Department of Justice
Healthtrust
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Cerilliant
Deloitte
AstraZeneca
Colorcon

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,144,872

« Back to Dashboard

Summary for Patent: 7,144,872
Title:N-pyrazole A.sub.2A receptor agonists
Abstract:This specification discloses 2-adenosine N-pyrazole compounds having the following formula: ##STR00001## and methods for using the compounds as A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.
Inventor(s): Zablocki; Jeff A. (Mountain View, CA), Elzein; Elfatih O. (Freemont, CA), Palle; Venkata (Gurgaon, IN), Belardinelli; Luiz (Palo Alto, CA)
Assignee: CV Therapeutics, Inc. (Palo Alto, CA)
Application Number:11/252,760
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Formulation;

Drugs Protected by US Patent 7,144,872

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF MYOCARDIAL IMAGING ➤ Sign Up
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION ➤ Sign Up
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,144,872

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,403,567 N-pyrazole A2A adenosine receptor agonists ➤ Sign Up
7,655,637 N-pyrazole A.sub.2A receptor agonists ➤ Sign Up
8,278,435 N-pyrazole A2A receptor agonists ➤ Sign Up
9,045,519 N-pyrazole A.sub.2A receptor agonists ➤ Sign Up
8,569,260 N-pyrazole A.sub.2A receptor agonists ➤ Sign Up
6,642,210 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists ➤ Sign Up
7,183,264 N-pyrazole A2A receptor agonists ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,144,872

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 024441 ➤ Sign Up
Austria 256141 ➤ Sign Up
Australia 7132400 ➤ Sign Up
Australia 760806 ➤ Sign Up
Brazil 0011856 ➤ Sign Up
Canada 2377746 ➤ Sign Up
China 1167709 ➤ Sign Up
China 1358191 ➤ Sign Up
Germany 122011000010 ➤ Sign Up
Germany 60007127 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Cipla
Farmers Insurance
Healthtrust
QuintilesIMS
Boehringer Ingelheim
Harvard Business School
Federal Trade Commission
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot